Introduction
Breast and prostate cancers are the leading cause of cancer-related death in women and men, respectively, in the United States (American Cancer Society, 2009 ). Many experimental approaches have been developed to identify genes and proteins that could be useful for the diagnosis or treatment of cancers (Chatterjee and Zetter, 2005) . To identify genes that encode membrane-associated or secreted proteins present in breast and prostate cancers, but with limited expression in normal organs, we prepared a cDNA library from a membrane-associated poly-ribosomal RNA isolated from breast and prostate cancer cell lines enriched in RNAs encoding membrane or secreted proteins (Egland et al., 2003) . From this library, we isolated a cDNA encoding CAPC, also known as LRRC26 (gene ID: 389816) . We observed that the CAPC RNA is present in many breast, prostate, colon and pancreatic cancers, but in normal tissues its expression is limited to the prostate and salivary gland (Egland et al., 2006) . These findings suggest an important role of CAPC in cancer biology, and point to its potential value as a tumor marker or therapeutic target.
In this report, we describe the biological properties of the CAPC protein. To do this we prepared a monoclonal Ab (mAb) that specifically reacts with CAPC and used it to characterize the protein in tumor cell lines. We found that knockdown of CAPC protein can stimulate anchorage-independent growth in the LNCaP cell line and that overexpression of CAPC suppressed tumor cell growth in vitro and in vivo. We also demonstrated that CAPC overexpression can suppress breast cell metastasis into lung. Our data indicate that CAPC inhibits tumor cell proliferation and tumor growth by regulating nuclear factor-kB (NF-kB) and its target genes, as well as many secreted proteins. Figure 1a shows that the CAPC mAb recognizes a 37 kDa doublet in a stably transfected line MDA-CAPC-18 but not in untransfected cells. We then used the mAb to investigate CAPC expression in normal tissues and cancer cell lines. We found that it detected very high CAPC protein expression in the prostate cancer cell line LNCaP, moderate expression in the breast cancer cell line HTB-20 (BT474) and low expression in MCF7. We did not detect the protein in MDA-435 cells (Figure 1b) . We also detected the CAPC protein in the prostate and salivary gland (Figure 1c) . No band was detected in the pituitary gland where there is no RNA expression. Interestingly, there is no detectable protein expression in the prostate tumor sample (Figure 1c, , which is from the same patient from which the normal prostate tissue was obtained (Figure 1c, lane-1 ).
Results

Characterization of CAPC protein by mAb
The predicated size of the CAPC protein is 35 kDa. In western blots we observed multiple bands above 35 kDa, suggesting protein modification (Figure 1a ). To determine whether the CAPC protein is glycosylated, an NP-40-solubilized cell lysate was treated with PNGase-F, which removes oligosaccharides from N-linked glycoproteins. As shown in Figure 1d , after treatment of PNGase the high-molecular-weight band disappeared and the 35-kDa band increased in intensity, indicating CAPC is an N-glycosylated protein. The CAPC protein may contain other modifications, because after PNGase treatment we still observed double bands near 35 kDa. To determine whether CAPC is a membrane protein, we separated the membrane fraction from the cytosolic fraction. CAPC was present in the membrane fraction ( Figure 1e ) but moved to the soluble fraction when 1% NP-40 was present. The CAPC protein was not solubilized by 2 M urea or high salt (data not shown), indicating that CAPC is an integral membrane protein.
To clarify the organelle in which CAPC was located, we used an MCF7 cell line stably expressing the CAPC-myc-tag protein. The expressing cells were double stained using both monoclonal anti-CAPC and polyclonal anti-myc Ab. The two Abs colocalized exactly in the merged image (data not shown), indicating the CAPC Ab recognized the same protein as the antimyc-tag Ab. CAPC-myc expression was then followed by staining the myc-tag using an anti-myc Ab and either an anti-protein disulfide isomerase (PDI), an endoplastic reticulum protein marker or an anti-pan-cytokeratin antibody. The green fluorescence (myc-tag on CAPC) exactly merged with the red PDI staining of the endoplastic reticulum (Figure 1f , red) but not with the pan-cytokeratin Ab (Figure 1i , red), indicating CAPC localized to the endoplastic reticulum. Also the specific CAPC staining did not colocalize with a trans-Golgi marker TGN46 (data not shown). Previously, CAPC was characterized by a rabbit polyclonal Ab, which recognized a 50-kDa endogenous protein in addition to the overexpressed 37-kDa CAPC by western blotting (Egland et al., 2006) . Using immunoprecipitation and gas chromatography-mass spectrometry (GC-MS) we have found that the 50-kDa protein, recognized by the polyclonal anti-CAPC Ab in previous studies, is not CAPC but cytokeratin-8 (data not shown). This explains why the CAPC protein was previously reported to be associated with cytokeratin in microfilaments (Egland et al., 2006) .
Knockdown of CAPC stimulated prostate tumor cell growth in soft agar To study the role of CAPC in cancer, we first investigated the human prostate tumor cell line LNCaP, which expresses CAPC at very high levels (Figure 1b , lane-1). The CAPC protein was efficiently knocked down by transfecting a short small interfering RNA (siRNA) oligo (Figure 2a) . Knockdown of CAPC did not affect cell proliferation in standard tissue culture (Figure 2b) . To examine the possible role of CAPC in tumorigenicity, we assessed the anchorage-independent growth of cells treated with CAPC siRNA in comparison with a luciferase siRNA control. When LNCaP cells treated with a control siRNA were plated into soft agar, only a few small colonies developed in 2 weeks. By contrast, after knockdown of CAPC with a specific siRNA, many colonies appeared (Figure 2c, d ).
Overexpression of CAPC suppressed the tumor development of a breast cancer cell line We established two CAPC-expressing cell lines, MDA-CAPC-18 and MDA-CAPC-19, from the highly invasive human breast cancer cell line MDA-231. The CAPC protein expression in the parental cell line was undetectable ( Figure 3a , lane-1). We measured the growth rate of the MDA-CAPC-18 and MDA-CAPC-19 lines in cell culture and found that overexpression of CAPC did not affect the growth rate of the cells over 4 days (Figure 3b ). We then measured the growth of the cells in soft agar and found that the MDA-231 cells formed 200-300 colonies per well, whereas the CAPC-18 and CAPC-19 lines did not form colonies (Figure 3c ).
To confirm that the growth inhibition in soft agar is due to CAPC expression, we knocked down CAPC expression by siRNA in the MDA-CAPC-18 line. We found that the CAPC protein expression was decreased by 90-100% at 48 h (Figure 3d ), and remained low for up to 1 week (data not shown). After CAPC knockdown, the MDA-CAPC-18 cells were capable of forming colonies in soft agar (Figure 3e ), indicating that the suppression of the growth of tumor cells in soft agar is caused by CAPC.
We then investigated the role of CAPC expression for xenograft tumor growth in immunodeficient mice. We rapidly grew into large tumors, which reached a volume of 1000 mm 3 in 2 weeks, whereas the two CAPCexpressing cell lines developed tumors much more slowly (Figure 4d ). These data show that CAPC suppression of tumor cell growth is not limited to a breast cancer cell line.
Expression of CAPC suppresses breast tumor metastasis to lung It has been shown previously that MDA-231 cells form lung tumors when injected intravenously into SCID mice and is a model of metastasis (Nam et al., 2006) . To address the role of CAPC in metastasis, 1 Â 10 6 MDA-231 or MDA-CAPC-18 cells were injected into the tail vein of SCID mice. After 6 weeks, 5/5 mice injected with MDA-231 cells had lung tumor metastasis (data not shown), and at 8 weeks 4/4 of the MDA-231 group showed very extensive tumor cell infiltration of the lung (Figure 5, top) . By contrast, 4/4 mice receiving MDA-CAPC-18 cells were free of lung tumors ( Figure 5 , bottom) in 8 weeks. In a separate experiment, we found that 4/5 mice in the MDA-231 group died with lung metastasis at week 9, but none of the mice in the MDA-CAPC-18 group died (data not shown). These results indicate that overexpression of CAPC suppressed metastatic growth.
Overexpression of CAPC downregulates secreted proteins, NF-kB and a spectrum of cytokines and chemoattractants in tumor cells
To investigate the mechanism of CAPC regulation of tumor cell growth, RNA samples from MDA-CAPC-18 and MDA-231 cells were analyzed by Illumina bead arrays containing 24 000 genes. The assembled microarray data were analyzed to identify the genes and pathways that were affected by CAPC overexpression. The data show that CAPC negatively regulates the NFkB pathway, the local acute inflammatory response (lair) pathway and the inflammation pathway by more than 10-fold (Supplementary Figure 1a) . We identified six genes that are positively regulated by more than twofold when CAPC is overexpressed and 48 genes that are negatively regulated by more than two-fold (Supplementary Table 1 ). Of the 54 genes regulated by CAPC, 42 (78%) encode secreted or membrane anchored proteins, 10 encode cytoplasmic or nuclear proteins, and two encode uncharacterized open reading frames.
To confirm the microarray data, we chose a group of negatively regulated genes from the microarray list and performed real-time PCR. As shown in Figure 6a , the mRNA levels for seven genes were lowered by expression of CAPC. Cytokines SAA2, and CSF2 and LTB1 were downregulated approximately five-fold and interleukin-8 (IL8) and CXCL1 were decreased 1.5-to 2.5-fold. Two other secreted proteins, the cysteine protease inhibitor cystatin SN (CST1) and the serine protease mesotrypsin (PRSS3), were decreased by 10-to 100-fold.
To determine whether CAPC negatively regulated the cytokine or chemokine genes in another cell line, we performed real-time PCR after knockdown of CAPC in LNCaP cells. When CAPC RNA levels were decreased by 60%, CXCL1, IL6, IL8, LTB1 and SAA2 were increased between 4-and 17-fold compared with the control siRNA (Figure 6b ). We also found that CSF2, protease PRSS3 and CST1 were not affected (data not shown). It is possible that a 60% decrease in CAPC mRNA was not sufficient to induce a change in their RNA or that there are cell type effects of CAPC.
The genes most affected, as identified by the microarray analysis (Supplementary Table 1) , are cytokines or chemokines. To determine whether the RNAs were translated into protein, we used a chemokine protein array. Cell culture medium collected from MDA-231 or MDA-CAPC-18 cells was analyzed. As shown in Figure 6c , the most significantly affected protein is CSF2 (granulocyte-macrophage colony-stimulating factor (GM-CSF), spot-1). CXCL1 (Groa, spot-2), IL6 (spot-3) and IL8 (spot-4) are also suppressed by CAPC with 1.5-to 3-fold changes (see also lower exposure in Supplementary Figure 1b) . The downregulation of these four proteins is consistent with real-time PCR analysis. Additionally, the cytokine CCL5 (spot-7) was downregulated. Interestingly, CAPC upregulated the cytokine IL1ra (IL1F3, spot-8), which is an inhibitor of IL1 action (Apte et al., 2006) . In summary, CAPC overexpression downregulated the pro-inflammatory cytokines (IL6, IL8, CSF2, CXCL1, CCL5) and upregulated an anti-inflammatory cytokine (IL1ra).
As most of the genes affected by CAPC are NF-kB targets, we investigated whether NF-kB activation is affected by overexpression of CAPC. NF-kB exists as an inactive complex in the cytoplasm in unstimulated cells. However, in some transformed tumor cells, NF-kB is activated and is found in the nucleus (Pacifico and Figure 5 Lung metastasis of the breast tumor lines MDA-231 and MDA-CAPC-18. MDA-231 or MDA-CAPC-18 cells were injected into athymic mice through the tail vein. After 8 weeks, the lungs were fixed and photographs were taken (top left, lung injected with MDA-231; bottom, MDA-CAPC-18). The right two panels are representative lungs sectioned and stained using hematoxylin and eosin to show the morphology of the lung and lung tumors ( Â 100). Leonardi, 2006; Lee et al., 2007) . We examined whether the amount of NF-kB in the nuclear fraction in MDA-231 cells was changed by CAPC overexpression. Figures 6d and e show that NF-kB is reduced 2-to 3-fold in the nuclei of MDA-CAPC-18 cells as compared with the parental MDA-231 cells. To confirm the negative regulation of NF-kB activity by CAPC, we performed NF-kB luciferase assays. As shown in Figure 6f , overexpression of CAPC significantly downregulated transcription from the NF-kB promoterreporter constructs in both MDA-231 and MCF7 cells. These results indicate that overexpression of CAPC suppresses the constitutive NF-kB activation in these tumor cells.
Recently, CAPC was identified as an auxiliary protein allowing BK potassium channel activation without calcium (Yan and Aldrich, 2010) . We investigated whether CAPC regulation of NF-kB activation is dependent on BK channel. As there is no detectable BKa protein in MDA-231 cells (data not shown), we used MCF7 and LNCaP. As seen in Supplementary  Figure 2 , CAPC overexpression suppressed NF-kB activity in the MCF7 cell line as expected; however, knockdown of BKa protein by siRNA did not affect NF-kB activity as measured by the luciferase assay in either the MCF7 or the MCF7-CAPC cell line. Additionally, knockdown of BKa protein did not affect the NF-kB activity in LNCaP cells. These results indicated that CAPC regulation of NF-kB activity is independent of the BK channel.
CAPC effect on tumor xenografts
As CAPC expression downregulated a set of genes encoding secreted proteins in vitro, we studied the same set of genes in tumor xenografts. As shown in Figure 7a , the chemokine/cytokines CXCL1, IL8, LTB1, protease PRSS3 and cystatin SN (CST1) were dramatically decreased in MDA-231 tumors expressing CAPC as compared with the parental MDA-231 tumors. We also examined the histology of the tumor xenografts. As shown in Figure 7b , hematoxylin and eosin staining of sections from CAPC-expressing tumors show that there were substantially fewer tumor cells and much more extracellular matrix (ECM). Treating the sections with Masson stain indicated the presence of substantial amounts of collagen type-I in the ECM. Furthermore, the number of proliferating cells as determined by Ki67 staining was reduced, whereas the number of apoptotic cells as determined by staining for cleaved caspase-3 was unchanged. These results indicate that CAPC expression inhibited tumor cell proliferation and greatly modified the tumor microenvironment.
Discussion
CAPC was discovered in a search for protein targets for Ab-based therapies. The goal was to find proteins located on the plasma membrane of cancer cells that were not expressed on essential normal organs such as liver, kidney, colon and brain, so that elimination of the cancer cells would not damage essential organs. In this approach, expression in non-essential organs is not a serious limitation, because these organs are often removed as part of cancer treatment. The only normal tissues that express CAPC are the prostate and salivary gland, two tissues that have a major secretary function. When we examined three prostate cancer lines for CAPC expression, we found CAPC protein expression in LNCaP but not in poorly differentiated PC3 and DU145 cells. These data indicate that CAPC is a differentiation antigen that has an important function in normal prostate and continues to be expressed in cancers arising in the prostate.
Because CAPC is highly expressed in normal prostate, we examined its function in LNCaP cells and found that lowering CAPC expression by RNA interference led to a striking increase in the ability of these cells to form colonies in soft agar consistent, with an increase in tumorigenicity. Next, because breast cancers frequently express CAPC, we investigated its function in breast cancer by introducing CAPC into the MDA-231 line that has undetectable CAPC protein and found that these cells had a decreased ability to grow in soft agar and to form tumors in nude mice. In addition, we examined the ability of the cells to grow in the lungs of mice after intravenous injection and found that increased CAPC also decreased tumor growth in this assay, which is used to measure metastatic capacity. Furthermore, lowering CAPC levels in the CAPCexpressing MDA-231 cells restored the ability to grow in soft agar. To determine whether this inhibitory effect of CAPC was more general, we used the A431 cancer line and again observed that CAPC-overexpressing cells were less tumorigenic in animals and in the soft agar assay, even though the growth rate in standard cell culture was unaffected. Furthermore, CAPC expression in the breast cancer cell line demonstrated by western blots (Figure 1b) correlate with the invasiveness of the cells: the highly invasive cell lines MDA-231 and MDA-435 have no or weak expression and the weakly invasive cells MCF7 and HTB-20 showed moderate levels of CAPC protein. These data suggest that CAPC expression was related to cancer cell behavior. Although we previously reported CAPC RNA to be expressed in breast tumor samples by reverse transcription-PCR (Egland et al., 2006) , we could not detect any CAPC protein by either immunohistochemistry or by western blotting (data not shown). Similarly, CAPC RNA was detected in the human lung sample by reverse transcription-PCR (Egland et al., 2006) , but the protein is undetectable by western blotting (data not shown). In tumor cells, CAPC protein expression is probably very low, so they can evade the suppressing effects of the CAPC protein on tumor growth and metastasis.
We found that three pathways were downregulated over 10-fold by CAPC overexpression. These are the NF-kB-induced pathway (Dixit and Mak, 2002; Naugler and Karin, 2008) and the local acute inflammation response and inflammatory pathways (Karin and Greten, 2005; Loza et al., 2007) . All three pathways have been implicated in cancer progression and metastases (Siebenlist and Franzoso, 1994; Lee et al., 2007; Park et al., 2007; Raman et al., 2007; Porta et al., 2009; Wu and Zhou, 2009; Li and Sethi, 2010) . Our microarray analysis showed that CXCL1, IL8, LTB1, CSF2 and SAA2 are downregulated 2-to 5-fold and we confirmed that these were decreased by using a protein array (Figure 6 ). These cytokines or chemokines were also decreased in mouse tumor xenografts (Figure 7) . Measurements of NF-kB activity showed that it was decreased in cells overexpressing CAPC. The NF-kB pathway is a crucial mediator of inflammation-induced tumor growth and progression. Other studies have shown that NF-kB inhibition can reduce the incidence of cancers of colon, lung and Hodgkin's lymphoma (Karin and Greten, 2005; Wang et al., 2009) . CAPC suppression of tumor growth may, in part, be due to the suppression of NF-kB activity and its downstream targets. An alternate explanation is that knockdown or overexpression of CAPC affected the tumor-initiating cells (or cancer stem cells), which would affect tumor development.
Cell-surface proteases degrade and remodel the ECM to help the dissemination of cancer cells into normal adjacent tissues. Cancer cells use secreted metalloproteinases, serine proteases and cathepsins to cleave and remove different types of ECM substrates, including collagen (Basbaum and Werb, 1996; Lee et al., 2004; Friedi and Wolk, 2008; Joyce and Pollard, 2009 ). We found tumors and cells overexpressing CAPC had decreased expression of the genes PRSS3 and CST1. PRSS3 has been found to promote the growth of breast cancer cells, and knockdown of PRSS3 attenuated cancer cell growth (Hockla et al., 2010) . The function of CST1 is still unclear, but it contributes to tumor cell proliferation and its expression was linked positively to many types of cancer, including gastric cancer and colon cancer in humans (Choi et al., 2009; Yoneda et al., 2009) . We also found that CAPC expression promoted the accumulation of collagen presumably by inhibiting its degradation as CAPC expression did not increase collagen mRNA levels in tumors (unpublished data). Our findings support the role of PRSS3 and CST1 in promoting tumor development. Thus expression of CAPC can suppress the pro-tumorigenesis factors and change the tumor microenvironment to decrease tumor cell proliferation, malignant progression and metastasis.
Materials and methods
Cell culture
The human breast cancer cell lines MCF7, MDA-MB-435, MDA-MB-231 (MDA-231) and HTB-20, and the prostate cancer cell line LNCaP were cultured in RPMI, and A431 epidermoid carcinoma cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin in a humidified atmosphere of 5% CO 2 . To establish CAPC stable lines, 2 mg of the plasmid pcDNA3-CAPC were transfected into cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in sixwell dishes. CAPC stably transfected cells were selected with either 500 mg/ml (MDA-231) or 750 mg/ml (A431 and MCF7) G418 for 2 weeks. Individual clones were selected and grown in the presence of G418. Control lines (transfected vector only) were selected by using the same concentration of G418.
Generation of mAb
The monoclonal anti-CAPC Ab was generated by using the C-terminal 14 amino acids (ARRRRLRTAALRPP) to immunize mice in collaboration with BD Pharmingen (San Diego, CA, USA).
Cell proliferation assay
Cells were plated in 96-well plates at 2000 cells per well. The cells were allowed to adhere overnight and growth was measured by the CCK-8 colorimetric growth assay (Dojindo, Rockville, MD, USA).
siRNA All cells were transfected with a short oligo siRNA by using the Amaxa system (Lonza, Cologne, Germany) following the manufacturer's instructions. The target sequence for CAPC is 5 0 -CGGGCUGCACUCGGUGC-3 0 (Dharmacon, Lafayette, CO, USA).
Western blot analysis and membrane fractionation Cells were washed in phosphate-buffered saline and lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA) with 1% NP-40, 5 mg/ml leupeptin, 5 mg/ml aprotinin, 10 mM phenylmethyl sulfonyl fluoride. The cytoplasmic and nuclear fractions were isolated by using a kit from Pierce (Rockford, IL, USA). For the membrane fractionation, cell pellets were washed with phosphate-buffered saline and suspended in lysis buffer without NP-40 and divided into three aliquots. One served as a no detergent, no salt control. NP-40 was added to another at a final concentration of 1% NP-40. The other was exposed to 2 M urea. After high-speed centrifugation, the supernatant and pellets were subjected to sodium dodecyl sulfate-PAGE and western blot analysis.
Luciferase assay Cells were transfected with NF-kB-RE and Renilla (pGL4.32 and pGL4.74, respectively) (Promega, Madison, WI, USA) for 48 h by using nucleofector (Lonza). Dual-Glo luciferase assays were performed following the manufacturer's instruction.
Cytokine array MDA-231 and MDA-CAPC-18 cells (both at 8 Â 10 5 ) were cultured in 60-mm dishes in 2 ml medium for 2 days. A 1-ml volume of media was centrifuged to remove cell debris and applied to a human cytokine array (Panel A array kit; R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
Immunofluorescence microscopy Cells growing on coverslips were fixed in 4% paraformaldehyde at room temperature for 20 min. The samples were blocked with buffer containing 3% bovine serum albumin, 0.05% Tween-20 in phosphate-buffered saline and incubated with the primary Ab with anti-myc, 9E10 (Cell Signaling, Danvers, MA, USA), anti-PDI or anti-pan-cytokeratin (Sigma, St Louis, MO, USA) in blocking buffer for 1-2 h, followed by Alex Flour-conjugated secondary antibodies (Invitrogen). Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Images were taken by confocal microscopy using a Zeiss 510 LSM.
Anchorage-independent soft agar assays For soft agar assays, 4000 cells were plated in 1.5 ml of Dulbecco's modified Eagle's medium containing 0.3% soft agarose, overlaid on 1.5 ml of 0.7% agarose in six-well dishes. The cultures were maintained for 15-21 days. Colonies from triplicate wells were stained by 0.05% crystal violet and visible colonies were counted by eye.
Tumor xenografts
Animals were maintained according to the NIH Animal Care and Use Committee guidelines under approved animal study protocols. Cells (5 Â 10 6 ) were suspended in 200 ml of phosphate-buffered saline and injected subcutaneously into either the right thoracic mammary fat pads of female nude mice (MDA-231 and MDA-231-CAPC) or into the rear flanks of nude mice (A431 and A431-CAPC), with five mice in each group. Tumor dimensions were determined every 2-3 days using calipers. Tumor volume (mm 3 ) was calculated by using the following formula: (a) Â (b 2 ) Â 0.4, where a is tumor length and b is tumor width in centimeters. Two-week-old tumor xenografts were removed for real-time PCR analysis and histology.
In vivo metastasis assays and histology One million cells from MDA-231 or MDA-CAPC-18 were injected into the tail vain of SCID mice. After killing the mice, the lungs were removed and fixed with formalin. A representative lung from each group was sent to Histoserve (Gaithersburg, MD, USA) for sectioning and staining using hematoxylin and eosin, Masson stain and for immunohistochemical detection of anti-Ki67 or anti-cleaved caspase-3.
